Genenta Science SPA

GNTA05 Dec 2024
Healthcare
$5.25
+0.03 (+2.52%)
Lowest Today
$5.15
Highest Today
$5.25
Today’s Open
$5.25
Prev. Close
$5.12
52 Week High
$7.28
52 Week Low
$2.2
To Invest in Genenta Science SPA

Genenta Science SPA

Healthcare
GNTA05 Dec 2024
+0.03 (+2.52%)
1M
3M
6M
1Y
5Y
Low
$5.15
Day’s Range
High
$5.25
5.15
52 Week Low
$2.2
52-Week Range
52 Week High
$7.28
2.2
1 Day
-
1 Week
-1.73%
1 month return
+9.44%
3 month return
+11.59%
6 month return
+54.54%
1 Year return
-
3 Years return
-53.16%
5 Years return
-
10 Years return
-
Institutional Holdings
Eurizon Azioni Internazionali
1.31
AlTi Global Inc
1.1
Kairos Intl SICAV Italia P
1.09
Kairos Intl SICAV Made in Italy Y
0.57
Mediolanum Flessibile Futuro Italia LA
0.54
Anthilia Small Cap Italia A
0.48
Investitori Flessibile
0.3

Market Status

Fundamentals
Market Cap
93.67 mln
PB Ratio
5.3
PE Ratio
0
Enterprise Value
79.11 mln
Total Assets
22.35 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Organisation
Genenta Science SPA
Employees
14
Industry
Biotechnology
CEO
Mr. Pierluigi  Paracchi
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step